WIC
SRPT icon

Willis Investment Counsel’s Sarepta Therapeutics SRPT Stock Holding History

Willis Investment Counsel’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,340
Closed -$249K – 121
2021
Q1 		$249K Buy
+3,340
New +$308K 0.02% 112

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Willis Investment Counsel's SRPT Position: Q2 2021 in Review

Willis Investment Counsel sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 3,340 shares — an estimated $249K sold.

Willis Investment Counsel first reported a position in SRPT in Q1 2021 and held it in 1 quarter. The position peaked at $249K in Q1 2021. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Willis Investment Counsel reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Willis Investment Counsel sold 3,340 Sarepta Therapeutics shares in Q2 2021, an estimated $249K.
  • Willis Investment Counsel first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 1 quarter.
  • Willis Investment Counsel's Sarepta Therapeutics position peaked at $249K in Q1 2021.
  • 330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Willis Investment Counsel's 13F filing for Q2 2021, filed 13 Aug 2021.